VJHemOnc is committed to improving our service to you

ASH 2019 | Daratumumab with IRd in NDMM displays excellent activity

VJHemOnc is committed to improving our service to you

Morie Gertz

Morie Gertz, MD, MACP, Mayo Clinic College of Medicine, Rochester, MN, discusses a phase II trial (NCT03012880) designed to examine the safety and efficacy of daratumumab in combination with an all-oral regimen of ixazomib, lenalidomide and modified dose dexamethasone (IRd) in newly diagnosed multiple myeloma (NDMM). Dr Gertz outlines the advantages of this drug regimen and reveals that the combination of daratumumab with IRd is well-tolerated and exhibits excellent activity, including in patients with high-risk genetics. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter